King's College London

Research portal

Translating genome-wide association findings into new therapeutics for psychiatry

Research output: Contribution to journalArticlepeer-review

Gerome Breen, Qingqin Li, Bryan L Roth, Patricio O'donnell, Michael Didriksen, Ricardo Dolmetsch, Paul F O'reilly, Héléna A Gaspar, Husseini Manji, Christopher Huebel, John R Kelsoe, Dheeraj Malhotra, Alessandro Bertolino, Danielle Posthuma, Pamela Sklar, Shitij Kapur, Patrick F Sullivan, David A Collier, Howard J Edenberg

Original languageEnglish
Pages (from-to)1392-1396
JournalNature Neuroscience
Issue number11
Early online date26 Oct 2016
E-pub ahead of print26 Oct 2016
PublishedNov 2016

King's Authors


Genome-wide association studies (GWAS) in psychiatry, once they reach sufficient sample size and power, have been enormously successful. The Psychiatric Genomics Consortium (PGC) aims for mega-analyses with sample sizes that will grow to >1 million individuals in the next 5 years. This should lead to hundreds of new findings for common genetic variants across nine psychiatric disorders studied by the PGC. The new targets discovered by GWAS have the potential to restart largely stalled psychiatric drug development pipelines, and the translation of GWAS findings into the clinic is a key aim of the recently funded phase 3 of the PGC. This is not without considerable technical challenges. These approaches complement the other main aim of GWAS studies, risk prediction approaches for improving detection, differential diagnosis, and clinical trial design. This paper outlines the motivations, technical and analytical issues, and the plans for translating PGC phase 3 findings into new therapeutics.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454